Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies

Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocco, Joseph M., Rosen, Lindsey B., Hong, Gloria H., Treat, Jennifer, Kreuzburg, Samantha, Holland, Steven M., Zerbe, Christa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141761/
https://www.ncbi.nlm.nih.gov/pubmed/34041472
http://dx.doi.org/10.1016/j.jtauto.2021.100102
_version_ 1783696433513234432
author Rocco, Joseph M.
Rosen, Lindsey B.
Hong, Gloria H.
Treat, Jennifer
Kreuzburg, Samantha
Holland, Steven M.
Zerbe, Christa S.
author_facet Rocco, Joseph M.
Rosen, Lindsey B.
Hong, Gloria H.
Treat, Jennifer
Kreuzburg, Samantha
Holland, Steven M.
Zerbe, Christa S.
author_sort Rocco, Joseph M.
collection PubMed
description Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to reduce autoantibodies leading to clinical and radiographic improvement in infection.
format Online
Article
Text
id pubmed-8141761
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81417612021-05-25 Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies Rocco, Joseph M. Rosen, Lindsey B. Hong, Gloria H. Treat, Jennifer Kreuzburg, Samantha Holland, Steven M. Zerbe, Christa S. J Transl Autoimmun Case report Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to reduce autoantibodies leading to clinical and radiographic improvement in infection. Elsevier 2021-05-04 /pmc/articles/PMC8141761/ /pubmed/34041472 http://dx.doi.org/10.1016/j.jtauto.2021.100102 Text en © 2021 Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case report
Rocco, Joseph M.
Rosen, Lindsey B.
Hong, Gloria H.
Treat, Jennifer
Kreuzburg, Samantha
Holland, Steven M.
Zerbe, Christa S.
Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
title Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
title_full Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
title_fullStr Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
title_full_unstemmed Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
title_short Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
title_sort bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
topic Case report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141761/
https://www.ncbi.nlm.nih.gov/pubmed/34041472
http://dx.doi.org/10.1016/j.jtauto.2021.100102
work_keys_str_mv AT roccojosephm bortezomibtreatmentforrefractorynontuberculousmycobacterialinfectioninthesettingofinterferongammaautoantibodies
AT rosenlindseyb bortezomibtreatmentforrefractorynontuberculousmycobacterialinfectioninthesettingofinterferongammaautoantibodies
AT honggloriah bortezomibtreatmentforrefractorynontuberculousmycobacterialinfectioninthesettingofinterferongammaautoantibodies
AT treatjennifer bortezomibtreatmentforrefractorynontuberculousmycobacterialinfectioninthesettingofinterferongammaautoantibodies
AT kreuzburgsamantha bortezomibtreatmentforrefractorynontuberculousmycobacterialinfectioninthesettingofinterferongammaautoantibodies
AT hollandstevenm bortezomibtreatmentforrefractorynontuberculousmycobacterialinfectioninthesettingofinterferongammaautoantibodies
AT zerbechristas bortezomibtreatmentforrefractorynontuberculousmycobacterialinfectioninthesettingofinterferongammaautoantibodies

Ejemplares similares